Liver transplantation for hepatocellular carcinoma


Cite item

Full Text

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequent cancer, usually develops in cirrhotic liver. Liver transplantation (LT) is potentially curative treatment for HCC. A total of 50 patients with HCC underwent LT. Patients were divided and compared according to Milan criteria. Differences between pre - and post-operative assessment were evaluated. Overall survival (OS) and disease-free survival (DFS) were compared between groups. Patients within MC had a significant better 1-, 3- and 5-year survival than a control group: 100, 100, 87,5% vs. 58, 41 and 27% for DFS and 100, 100, 87,5% vs. 76,9, 45 and 29,5% for OS.Conclusion: long-term results in patients with HCC after LT is excellent if tumor characteristics are within the Milan criteria.

About the authors

M Sh Khubutiya

SFHI N.V.Sklifosovsky Research Institute for Emergency Care Moscow City Health Department

чл.-кор. РАН, д-р мед. наук, проф., дир. НИИ СП им. Н.В.Склифосовского 129010, Russian Federation, Moscow, Bol'shaia Sukharevskaia ploshchad', d. 3

M S Novruzbekov

SFHI N.V.Sklifosovsky Research Institute for Emergency Care Moscow City Health Department

канд. мед. наук, и.о. зав. науч. отд. трансплантации печени НИИ СП им. Н.В.Склифосовского 129010, Russian Federation, Moscow, Bol'shaia Sukharevskaia ploshchad', d. 3

O D Olisov

SFHI N.V.Sklifosovsky Research Institute for Emergency Care Moscow City Health Department

Email: dr.olisov@gmail.com
канд. мед. наук, ст. науч. сотр. отд. трансплантации печени НИИ СП им. Н.В.Склифосовского 129010, Russian Federation, Moscow, Bol'shaia Sukharevskaia ploshchad', d. 3

I E Galankina

SFHI N.V.Sklifosovsky Research Institute for Emergency Care Moscow City Health Department

д-р мед. наук, проф., зав. науч. отд. патологической анатомии НИИ СП им. Н.В.Склифосовского 129010, Russian Federation, Moscow, Bol'shaia Sukharevskaia ploshchad', d. 3

L N Zimina

SFHI N.V.Sklifosovsky Research Institute for Emergency Care Moscow City Health Department

д-р мед. наук, проф., вед. науч. сотр. отд. патологической анатомии НИИ СП им. Н.В.Склифосовского 129010, Russian Federation, Moscow, Bol'shaia Sukharevskaia ploshchad', d. 3

References

  1. Khan A.S, Fowler K.J, Chapman W.C. Current surgical treatment strategies for hepatocellular carcinoma in North America. World J Gastroenterol 2014; 20 (41): 15 007-17.
  2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update (AASLD Practice Guideline). Hepatology 2010.
  3. Byam J, Renz J, Millis M. Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr 2013; 2 (1): 22-30.
  4. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
  5. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 2008; 8 (10): 1982-9.
  6. Yao F.Y, Ferrell L, Bass N.M et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.
  7. Duffy J.P, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246: 502-11.
  8. Xu X, Lu D, Ling Q et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut 2015.
  9. Mazzaferro V, Chun Y, Poon R et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncology 2003; 15 (4): 1001-7.
  10. Weledji E, Orock G, Ngowe M, Nsagha D.S. How grim is hepatocellular carcinoma? Ann Med Surgery 2014; 3: 71-6.
  11. Hackl C, Schlitt H, Kirchner G et al. Liver transplantation for malignancy: current treatment strategies and future perspectives. World J Gastroenterol 2014; 20 (18): 5331-44.
  12. Asham E.H, Mansour H, Ghobrial M. Liver transplantation for hepatocellular carcinoma. Cancer J 2014; 12; http://dx.doi.org/10.5772/55374
  13. Sapisochin G, Fernandez de Sevilla E, Echeverri J, Charco R. Management of «very early» hepatocellular carcinoma on cirrhotic patients. World J Hepatol 2014; 6 (11): 766-75.
  14. Sirivatanauksorn Y, Tovikkai C. Comparison of staging systems of hepatocellular carcinoma. HPB Surgery Volume 2011. ID 818217.
  15. Mazzaferro V et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
  16. Mazzaferro V, Bhoori S, Sposito C et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence - based analysis of 15 years of experience. Liver Transplantation 2011; 17: s44-57.
  17. Clavien P.A et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13(1): e11-22.
  18. Lei J, Wang W, Yan L. Up - to - seven criteria for hepatocellular carcinoma liver transplantation: a single center analysis. World J Gastroenterol 2013; 19 (36): 6077-83.
  19. Bruix J, Raoul J-L, Sherman M, Mazzaferro V. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: sub - analyses of a phase III trial. J Hepatology 2012; 57: 821-9.
  20. Teng C, Hwang W, Chen Y et al. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study. World J Surg Oncology 2012; 10: 41.
  21. Saab S, McTigue M, Finn R.S, Busuttil R.W. Sorafenib as adjuvant therapy for high - risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010; 8 (4): 307-13.
  22. Waghray A, Balci B, El-Gazzaz G et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant 2013; 27: 555-61; http://10.1111/ctr.12150

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies